
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Risk factor modification remains key to managing patients with HIV and diabetes.
In this interview, filmed during the American Diabetes Association 78th Annual Scientific Sessions, Priscilla Hsue, MD, from the University of California San Francisco School of Medicine, discusses treating patients with HIV and diabetes.
Transcript
Priscilla Hsue, MD: So I think individuals with HIV and diabetes, they're at increased risk for things like cardiovascular disease. So I think really aggressive recognition of this increased risk, as well as risk factor modification, whether its with lipid lowering therapy, blood pressure medication, cigarette smoking, glucose management. So, all those would be critical.






